Doxyhyklan 10% Uses

Did you have any side effects with this medicine?
sponsored

What is Doxyhyklan 10%?

Doxyhyklan 10% is a tetracycline antibiotic that fights bacteria in the body.

Doxyhyklan 10% is used to treat many different bacterial infections, such as acne, urinary tract infections, intestinal infections, eye infections, gonorrhea, chlamydia, periodontitis (gum disease), and others.

Doxyhyklan 10% is also used to treat blemishes, bumps, and acne-like lesions caused by rosacea. Doxyhyklan 10% will not treat facial redness caused by rosacea.

Some forms of Doxyhyklan 10% are used to prevent malaria, to treat anthrax, or to treat infections caused by mites, ticks, or lice.

Doxyhyklan 10% may also be used for purposes not listed in this medication guide.

Doxyhyklan 10% indications

An indication is a term used for the list of condition or symptom or illness for which the medicine is prescribed or used by the patient. For example, acetaminophen or paracetamol is used for fever by the patient, or the doctor prescribes it for a headache or body pains. Now fever, headache and body pains are the indications of paracetamol. A patient should be aware of the indications of medications used for common conditions because they can be taken over the counter in the pharmacy meaning without prescription by the Physician.
sponsored

Rickettsial Infections

Doxyhyklan 10%® and Doxyhyklan 10%® CAP are indicated for treatment of Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsial pox, and tick fevers caused by Rickettsiae.

Sexually Transmitted Infections

Doxyhyklan 10% and Doxyhyklan 10% CAP are indicated for treatment of the following sexually transmitted infections:

Respiratory Tract Infections

Doxyhyklan 10% and Doxyhyklan 10% CAP are indicated for treatment of the following respiratory tract infections:

Specific Bacterial Infections

Doxyhyklan 10% and Doxyhyklan 10% CAP are indicated for treatment of the following specific bacterial infections:

Because many strains of the following groups of microorganisms have been shown to be resistant to Doxyhyklan 10%, culture and susceptibility testing are recommended.

Doxyhyklan 10% and Doxyhyklan 10% CAP are indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriological testing indicates appropriate susceptibility to the drug:

Ophthalmic Infections

Doxyhyklan 10% and Doxyhyklan 10% CAP are indicated for treatment of the following ophthalmic infections:

Anthrax Including Inhalational Anthrax (Post-Exposure)

Doxyhyklan 10% and Doxyhyklan 10% CAP are indicated for the treatment of Anthrax due to Bacillus anthracis, including inhalational anthrax (post-exposure); to reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis.

Alternative Treatment for Selected Infections when Penicillin is Contraindicated

Doxyhyklan 10% and Doxyhyklan 10% CAP are indicted as an alternative treatment for the following selected infections when penicillin is contraindicated:

Adjunctive Therapy for Acute Intestinal Amebiasis and Severe Acne

In acute intestinal amebiasis, Doxyhyklan 10% and Doxyhyklan 10% CAP may be a useful adjunct to amebicides.

In severe acne, Doxyhyklan 10% and Doxyhyklan 10% CAP may be useful adjunctive therapy.

Prophylaxis of Malaria

Doxyhyklan 10% and Doxyhyklan 10% CAP are indicated for the prophylaxis of malaria due to Plasmodium falciparum in short-term travelers (less than 4 months) to areas with chloroquine and/or pyrimethamine-sulfadoxine resistant strains.

Usage

To reduce the development of drug-resistant bacteria and maintain the effectiveness of Doxyhyklan 10% and Doxyhyklan 10% CAP and other antibacterial drugs, Doxyhyklan 10% and Doxyhyklan 10% CAP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.

How should I use Doxyhyklan 10%?

Use Doxyhyklan 10% kit as directed by your doctor. Check the label on the medicine for exact dosing instructions.

Ask your health care provider any questions you may have about how to use Doxyhyklan 10% kit.

Uses of Doxyhyklan 10% in details

There are specific as well as general uses of a drug or medicine. A medicine can be used to prevent a disease, treat a disease over a period or cure a disease. It can also be used to treat the particular symptom of the disease. The drug use depends on the form the patient takes it. It may be more useful in injection form or sometimes in tablet form. The drug can be used for a single troubling symptom or a life-threatening condition. While some medications can be stopped after few days, some drugs need to be continued for prolonged period to get the benefit from it.
sponsored

Use: Labeled Indications

Acne: Adjunctive therapy in severe acne.

Actinomycosis: Treatment of actinomycosis caused by Actinomyces israelii when penicillin is contraindicated.

Acute intestinal amebiasis: Adjunct to amebicides in acute intestinal amebiasis.

Anthrax, including inhalational anthrax (postexposure): Treatment of anthrax caused by Bacillus anthracis, including inhalational (postexposure) prophylaxis; to reduce the incidence or progression of disease following exposure to aerosolized B. anthracis.

Cholera: Treatment of cholera infections caused by Vibrio cholerae.

Clostridium: Treatment of infections caused by Clostridium spp. when penicillin is contraindicated.

Gram-negative infections: Treatment of infections caused by Escherichia coli, Enterobacter aerogenes, Shigella spp., Acinetobacter spp., Klebsiella spp. (respiratory and urinary infections), and Bacteroides spp.; Neisseria meningitidis (when penicillin is contraindicated).

Gram-positive infections: Treatment of infections caused by Streptococcus spp., when susceptible.

Listeriosis: Treatment of listeriosis due to Listeria monocytogenes when penicillin is contraindicated.

Malaria prophylaxis: Prophylaxis of malaria due to Plasmodium falciparum in short-term travelers (under 4 months) to areas with chloroquine and/or pyrimethamine-sulfadoxine-resistant strains.

Mycoplasma pneumoniae: Treatment of infections caused by Mycoplasma pneumoniae.

Ophthalmic infections:

Treatment of inclusion conjunctivitis or trachoma caused by Chlamydia trachomatis.

Periodontitis (20 mg tablet and capsule [Periostat (Canadian product)] only): Adjunct to scaling and root planing to promote attachment level gain and to reduce pocket depth in patients with adult periodontitis.

Relapsing fever: Treatment of relapsing fever caused by Borrelia recurrentis.

Respiratory tract infections: Treatment of respiratory infections caused by Haemophilus influenzae, Klebsiella spp., or Mycoplasma pneumoniae; treatment of upper respiratory tract infections caused by Streptococcus pneumoniae; respiratory infections caused by Staphylococcus aureus (Doxyhyklan 10% is not the drug of choice in the treatment of any type of staphylococcal infection).

Rickettsial infections: Treatment of Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae.

Rosacea (Oracea, Apprilon [Canadian product] only): Treatment of only inflammatory lesions (papules and pustules) of rosacea in adults.

Sexually transmitted infections: Treatment of lymphogranuloma venereum and uncomplicated urethral, endocervical, or rectal infections caused by Chlamydia trachomatis; granuloma inguinale (donovanosis) caused by Klebsiella granulomatis; chancroid caused by Haemophilus ducreyi; nongonococcal urethritis caused by Ureaplasma urealyticum; when penicillin is contraindicated, uncomplicated gonorrhea caused by Neisseria gonorrhea and syphilis caused by Treponema pallidum.

Note: The CDC sexually transmitted disease guidelines recommend dual antimicrobial therapy be used for uncomplicated gonorrhea due to N. gonorrhea resistance concerns; ceftriaxone is the preferred cephalosporin and Doxyhyklan 10% is an alternative option for the second antimicrobial only in cases of azithromycin allergy (CDC [Workowski 2015]).

Skin and skin structure infections (Avidoxy only): Treatment of skin and skin structure infections caused by Staphylococcus aureus (Doxyhyklan 10% is not the drug of choice in the treatment of any type of staphylococcal infection).

Vincent infection: Treatment of Vincent infection caused by Fusobacterium fusiforme when penicillin is contraindicated.

Yaws: Treatment of yaws caused by Treponema pallidum subspecies pertenue when penicillin is contraindicated.

Zoonotic infections: Treatment of psittacosis (ornithosis) caused by Chlamydophila psittaci; plague due to Yersinia pestis; tularemia caused by Francisella tularensis; brucellosis caused by Brucella spp. (in conjunction with streptomycin); bartonellosis caused by Bartonella bacilliformis; infections caused by Campylobacter fetus.

Off Label Uses

Anaplasmosis and ehrlichiosis

Based on the IDSA guidelines for the clinical assessment, treatment, and prevention of Lyme disease, human granulocytic anaplasmosis (HGA) and babesiosis and the Centers for Disease Control and Prevention (CDC) guideline for the diagnosis and management of tickborne rickettsial diseases, Doxyhyklan 10% is effective and recommended for the treatment of human anaplasmosis (also known as HGA) and human ehrlichiosis.

Bartonella infections in HIV-infected patients

Based on the US Department of Health and Human Services (HHS) guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents, Doxyhyklan 10% is a recommended and effective agent for treatment of bacillary angiomatosis, peliosis hepatis, bacteremia, osteomyelitis, CNS infections, infective endocarditis, and other severe infections due to Bartonella in adolescent and adult HIV-infected patients.

Bite wound infection (animal or human bite)

Based on the IDSA guidelines for the diagnosis and management of SSTIs, Doxyhyklan 10% is an acceptable alternative agent for the prophylaxis and treatment of bite wounds (animal or human).

Cellulitis, mild to moderate

Based on the Infectious Diseases Society of America (IDSA) guidelines for the diagnosis and management of skin and soft tissue infections (SSTIs) and the treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections, Doxyhyklan 10% is an effective and recommended treatment option for SSTIs caused by MRSA, particularly purulent cellulitis due to community-acquired MRSA (CA-MRSA).

Chronic obstructive pulmonary disease, acute exacerbation

Data from a randomized, double-blind, placebo-controlled trial support the use of Doxyhyklan 10% in the treatment of acute exacerbation of chronic obstructive pulmonary disease (COPD).

Based on the American College of Chest Physicians diagnosis and management of lung cancer clinical practice guidelines, intrapleural Doxyhyklan 10% is effective and recommended in the management of recurrent, symptomatic, malignant pleural effusions.

Proctitis, acute or proctocolitis

Based on the CDC sexually transmitted diseases treatment guidelines, Doxyhyklan 10% in combination with ceftriaxone is an effective and recommended agent in the treatment of acute proctitis or proctocolitis.

Prosthetic joint infection

Based on the IDSA guidelines for the management of prosthetic joint infection, Doxyhyklan 10% is an effective and recommended agent for treatment (oral phase) of prosthetic joint infection and for chronic oral antimicrobial suppression of prosthetic joint infection due to staphylococci or Cutibacterium acnes.

Surgical prophylaxis, uterine evacuation (induced abortion or pregnancy loss)

Based on the American College of Obstetricians and Gynecologists guidelines for prevention of infection after gynecologic procedures, Doxyhyklan 10% is effective and recommended as antimicrobial prophylaxis for uterine evacuation procedures for induced abortion or pregnancy loss.

Doxyhyklan 10% description

sponsored

Doxyhyklan 10% is a broad-spectrum antibiotic synthetically derived from oxytetracycline and is available as Doxyhyklan 10% monohydrate and Doxyhyklan 10% hyclate (hydrochloride hemiethanolate hemihydrate). The chemical designation of this light-yellow crystalline powder is α-6-deoxy-5-oxytetracycline. Doxyhyklan 10% has a high degree of lipoid solubility and a low affinity for calcium binding. It is highly stable in normal human serum. Doxyhyklan 10% will not degrade into an epianhydro form.

The molecular formula for Doxyhyklan 10% hydrochloride hemiethanolate hemihydrate is (C22H24N2O8·HCl)2·C2H6O·H2O and the molecular weight is 1025.89. Doxyhyklan 10% is a light-yellow crystalline powder. Doxyhyklan 10% hyclate is soluble in water, while Doxyhyklan 10% monohydrate is very slightly soluble in water.

Doxyhyklan 10% dosage

Usual Dosage And Administration

The usual dosage and frequency of administration of Doxyhyklan 10% differs from that of the other tetracyclines. Exceeding the recommended dosage may result in an increased incidence of side effects.

Adults
Pediatric Patients

Administration of adequate amounts of fluid along with capsule and tablet forms of drugs in the tetracycline-class is recommended to wash down the drugs and reduce the risk of esophageal irritation and ulceration.

If gastric irritation occurs, Doxyhyklan 10% may be given with food or milk.

When used in streptococcal infections, therapy should be continued for 10 days.

Uncomplicated urethral, endocervical, or rectal infection caused by Chlamydia trachomatis: 100 mg by mouth twice a day for 7 days. As an alternate dosing regimen for uncomplicated urethral or endocervical infection caused by Chlamydia trachomatis, administer 200 mg by mouth once-a-day for 7 days.

Uncomplicated gonococcal infections in adults (except anorectal infections in men): 100 mg, by mouth, twice-a-day for 7 days. As an alternate single visit dose, administer 300 mg stat followed in one hour by a second 300 mg dose.

Nongonococcal urethritis (NGU) caused by U. urealyticum: 100 mg by mouth twice-aday for 7 days.

Syphilis – early: Patients who are allergic to penicillin should be treated with Doxyhyklan 10% 100 mg by mouth twice-a-day for 2 weeks.

Syphilis of more than one year's duration: Patients who are allergic to penicillin should be treated with Doxyhyklan 10% 100 mg by mouth twice-a-day for 4 weeks.

Acute epididymo-orchitis caused by C. trachomatis: 100 mg, by mouth, twice-a-day for at least 10 days.

For Prophylaxis Of Malaria

For adults, the recommended dose is 100 mg daily. For children over 8 years of age, the recommended dose is 2 mg/kg given once daily up to the adult dose. Prophylaxis should begin 1 or 2 days before travel to the malarious area. Prophylaxis should be continued daily during travel in the malarious area and for 4 weeks after the traveler leaves the malarious area.

Inhalational Anthrax (post-exposure)

Adults: 100 mg, of Doxyhyklan 10%, by mouth, twice-a-day for 60 days. Children: weighing less than 45 kg, 2.2 mg/kg of body weight, by mouth, twice-a-day for 60 days. Children weighing 45 kg or more should receive the adult dose.

Sprinkling The Tablet Over Applesauce

Doxyhyklan 10% Hyclate Delayed-Release Tablets may also be administered by carefully breaking up the tablet and sprinkling the tablet contents (delayed-release pellets) on a spoonful of applesauce. The delayed-release pellets must not be crushed or damaged when breaking up the tablet. Any loss of pellets in the transfer would prevent using the dose. The applesauce/Doxyhyklan 10% Hyclate Delayed-Release Tablets mixture should be swallowed immediately without chewing and may be followed by a glass of water if desired. The applesauce should not be hot, and it should be soft enough to be swallowed without chewing. In the event that a prepared dose of applesauce/Doxyhyklan 10% Hyclate Delayed-Release Tablets cannot be taken immediately, the mixture should be discarded and not stored for later use.

How supplied

Dosage Forms And Strengths

Doxyhyklan 10% Hyclate Delayed-Release Tablets, 75 mg are white, oval, scored tablets containing yellow pellets and debossed with “D|5” on one face and plain on the other. Each tablet contains specially coated pellets of Doxyhyklan 10% hyclate equivalent to 75 mg of Doxyhyklan 10%.

Doxyhyklan 10% Hyclate Delayed-Release Tablets, 100 mg are white, oval, scored tablets containing yellow pellets and debossed with “D|0” on one face and plain on the other. Each tablet contains specially coated pellets of Doxyhyklan 10% hyclate equivalent to 100 mg of Doxyhyklan 10%.

Doxyhyklan 10% Hyclate Delayed-Release Tablets, 150 mg are white, rectangular, dual scored tablets containing yellow pellets and debossed with “D|I|I” on one face and plain on the other. Each tablet contains specially coated pellets of Doxyhyklan 10% hyclate equivalent to 150 mg of Doxyhyklan 10%.

Doxyhyklan 10% Hyclate Delayed-Release Tablets, 200 mg are white, oval, scored tablets containing yellow pellets and debossed with “D|D” on one face and plain on the other. Each tablet contains specially coated pellets of Doxyhyklan 10% hyclate equivalent to 200 mg of Doxyhyklan 10%.

Storage And Handling

Doxyhyklan 10% Hyclate Delayed-Release Tablets, 75 mg are white, oval, scored tablets containing yellow pellets and debossed with “D|5” on one face and plain on the other. Each tablet contains specially coated pellets of Doxyhyklan 10% hyclate equivalent to 75 mg of Doxyhyklan 10%.

Bottles of 60 tablets NDC 68308-775-60

Doxyhyklan 10% Hyclate Delayed-Release Tablets, 100 mg are white, oval, scored tablets containing yellow pellets and debossed with “D|0” on one face and plain on the other. Each tablet contains specially coated pellets of Doxyhyklan 10% hyclate equivalent to 100 mg of Doxyhyklan 10%.

Bottles of 100 tablets NDC 68308-710-10

Doxyhyklan 10% Hyclate Delayed-Release Tablets, 150 mg are white, rectangular, dual scored tablets containing yellow pellets and debossed with “D|I|I” on one face and plain on the other. Each tablet contains specially coated pellets of Doxyhyklan 10% hyclate equivalent to 150 mg of Doxyhyklan 10%.

Bottles of 100 tablets NDC 68308-715-10

Doxyhyklan 10% Hyclate Delayed-Release Tablets, 200 mg are white, oval, scored tablets containing yellow pellets and debossed with “D|D” on one face and plain on the other. Each tablet contains specially coated pellets of Doxyhyklan 10% hyclate equivalent to 200 mg of Doxyhyklan 10%.

Bottles of 60 tablets NDC 68308-716-60

Store at 25° C (77° F); excursions permitted to 15 – 30° C (59 – 86° F). Dispense in a tight, light-resistant container (USP).

Distributed by: Mayne Pharma, Greenville, NC 27834 1-844-825-8500. Manufactured by: Mayne Pharma International Pty Ltd, Salisbury South, SA 5106 Australia. Revised: Apr 2016

Doxyhyklan 10% interactions

See also:
What other drugs will affect Doxyhyklan 10%?

sponsored

Medications containing metal ions (antacids, products containing iron, magnesium, calcium) form inactive chelates with Doxyhyklan 10%, in connection with what it is necessary to avoid their simultaneous use.

It needed to avoid combination with penicillins, cephalosporins, bactericidal action and is an antagonist of bacteriostatic antibiotics (including Doxyhyklan 10%).

Absorption of Doxyhyklan 10% is reduced by cholestyramine and colestipol (observe the interval between the reception of at least 3 h).

Due to suppression of intestinal microflora Doxyhyklan 10% reduces prothrombin index which requires dose adjustment of indirect anticoagulants.

Alti-Doxyhyklan 10% reduces the reliability of contraception and increases the frequency of breakthrough bleeding while taking estrogen-containing oral contraceptives.

Simultaneous administration of Alti-Doxyhyklan 10% with:

  • barbiturates, carbamazepine, phenytoin concentrations of Doxyhyklan 10% in plasma decreases due to the induction of liver enzymes, which may be responsible for the decrease of its antibacterial action.
  • retinol improves intracranial pressure.

    Doxyhyklan 10% side effects

    See also:
    What are the possible side effects of Doxyhyklan 10%?

    Clinical Trial Experience

    The safety and efficacy of Doxyhyklan 10% Hyclate Delayed-Release Tablets, 200 mg as a single daily dose was evaluated in a multicenter, randomized, double-blind, active-controlled study. Doxyhyklan 10% Hyclate Delayed-Release Tablets 200 mg was given orally once-a-day for 7 days and compared to Doxyhyklan 10% hyclate capsules 100 mg given orally twice daily for 7 days for the treatment of men and women with uncomplicated urogenital C. trachomatis infection.

    Adverse events in the Safety Population were reported by 99 (40.2%) subjects in the Doxyhyklan 10% Hyclate Delayed-Release Tablets, 200 mg treatment group and 132 (53.2%) subjects in the doxycyclinehyclate capsules reference treatment group. Most AEs were mild in intensity. The most commonly reported adverse events in both treatment groups were nausea, vomiting, diarrhea, and bacterial vaginitis, Table 1.

    Table 1: Adverse Reactions Reported in Greater than or Equal to 2% of Subjects

    Doxyhyklan 10% Hyclate Delayed-Release Tablets, 200 mg

    N = 246

    Preferred Term n (%)
    Subjects with any AE 99 (40.2)
    Nausea 33 (13.4)
    Vomiting 20 (8.1)
    Headache 5 (2.0)
    Diarrhea 8 (3.3)
    Abdominal Pain Upper 5 (2.0)
    Vaginitis Bacterial 8 (3.3)
    Vulvovaginal Mycotic Infection 5 (2.0)

    Because clinical trials are conducted under prescribed conditions, adverse reaction rates observed in the clinical trial may not always reflect the rates observed in practice.

    Postmarketing Experience

    The following adverse reactions have been identified during post-approval use of Doxyhyklan 10%. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate a causal relationship to drug exposure.

    Due to oral Doxyhyklan 10%'s virtually complete absorption, side effects to the lower bowel, particularly diarrhea, have been infrequent. The following adverse reactions have been observed in patients receiving tetracyclines:

    Gastrointestinal: Anorexia, nausea, vomiting, diarrhea, glossitis, dysphagia, enterocolitis, and inflammatory lesions (with monilial overgrowth) in the anogenital region. Hepatotoxicity has been reported. These reactions have been caused by both the oral and parenteral administration of tetracyclines. Esophagitis and esophageal ulcerations have been reported in patients receiving capsule and tablet forms of drugs in the tetracycline-class. Most of these patients took medications immediately before going to bed.

    Skin: Maculopapular and erythematous rashes, Stevens-Johnson syndrome, toxic epidermal necrolysis, exfoliative dermatitis, and erythema multiforme have been reported. Photosensitivity is discussed above.

    Renal: Rise in BUN has been reported and is apparently dose-related.

    Hypersensitivity reactions: Urticaria, angioneurotic edema, anaphylaxis, anaphylactoid purpura, serum sickness, pericarditis, and exacerbation of systemic lupus erythematosus.

    Blood: Hemolytic anemia, thrombocytopenia, neutropenia, and eosinophilia have been reported.

    Intracranial Hypertension: Intracranial hypertension (IH, pseudotumor cerebri) has been associated with the use of tetracycline

    Thyroid Gland Changes: When given over prolonged periods, tetracyclines have been reported to produce brown-black microscopic discoloration of thyroid glands. No abnormalities of thyroid function are known to occur.

    Doxyhyklan 10% contraindications

    See also:
    What is the most important information I should know about Doxyhyklan 10%?

    Do not use this medicine if you are pregnant. It could harm the unborn baby or cause permanent tooth discoloration later in life.

    Doxyhyklan 10% can make birth control pills less effective. Ask your doctor about using a non hormone method of birth control (such as a condom, diaphragm, spermicide) to prevent pregnancy while using Doxyhyklan 10%.

    You should not take this medicine if you are allergic to Doxyhyklan 10% or to other tetracycline antibiotics such as demeclocycline (Declomycin), minocycline (Dynacin, Minocin, Solodyn, Vectrin), or tetracycline (Brodspec, Panmycin, Sumycin, Tetracap).

    Before taking Doxyhyklan 10%, tell your doctor if you have liver disease, kidney disease, asthma, or if you are allergic to sulfites.

    Drink plenty of liquids while you are taking Doxyhyklan 10%.

    Children should not use Doxyhyklan 10%. Doxyhyklan 10% can cause permanent yellowing or graying of the teeth in children younger than 8 years old.

    Take this medication for the full prescribed length of time. Your symptoms may improve before the infection is completely cleared. Skipping doses may also increase your risk of further infection that is resistant to antibiotics.



    Active ingredient matches for Doxyhyklan 10%:

    Doxycycline in Poland.


    List of Doxyhyklan 10% substitutes (brand and generic names)

    Sort by popularity
    Unit description / dosage (Manufacturer)Price, USD
    Doxykan 100 mg Tablet (Kansas Laboratories Pvt. Ltd.)$ 0.01
    Doxyl 100 mg Capsule (LA Grande (P) Ltd)$ 0.05
    Doxylab 100 mg Capsule (Laborate Pharmaceuticals India Ltd.)$ 0.02
    DOXYLAB 100 MG CAPSULE 1 strip / 10 capsules each (Laborate Pharmaceuticals India Ltd.)$ 0.54
    Doxylab 100mg Capsule (Laborate Pharmaceuticals India Ltd.)$ 0.06
    Capsule; Oral; Doxycycline Hyclate 100 mg (Lagap)
    Capsules; Oral; Doxycycline Hyclate 100 mg (Lagap)
    Doxylan 10+10 Tablet (Atoz Pharmaceuticals (Zota Healthcare Pvt Ltd))$ 0.04
    Doxylcap 100 mg x 500's (Bangkok Lab & Cosmetic)
    Doxylcap 100 mg x 50 x 10's (Bangkok Lab & Cosmetic)
    Doxylcap 100 mg 50 x 10's (Bangkok Lab & Cosmetic)
    Doxylcap 100 mg 500's (Bangkok Lab & Cosmetic)
    Doxyleb 100mg CAP / 10 (Leben Laboratories Pvt. Ltd.)$ 0.18
    100 mg x 10's (Leben Laboratories Pvt. Ltd.)$ 0.18
    Doxyleb 100 mg Capsule (Leben Laboratories Pvt. Ltd.)$ 0.02
    DOXYLEB 100 MG CAPSULE 1 strip / 10 capsules each (Leben Laboratories Pvt. Ltd.)$ 0.24
    DOXYLEB cap 100 mg x 10's (Leben Laboratories Pvt. Ltd.)$ 0.18
    Doxyleb 100mg Capsule (Leben Laboratories Pvt. Ltd.)$ 0.02
    Tablet; Oral; Doxycycline Hyclate 100 mg (Active Healthcare)
    Tablet; Oral; Doxycycline Hyclate 50 mg (Active Healthcare)
    Doxylin 400mg TAB / 10 (Active Healthcare)$ 1.25
    Doxylin 100 mg x 10 x 10's (Active Healthcare)
    Doxylin 100 mg x 500's (Active Healthcare)
    Tablets; Oral; Doxycycline Hyclate 100 mg (Active Healthcare)
    Tablets; Oral; Doxycycline Hyclate 50 mg (Active Healthcare)
    Doxylin 400 mg Tablet (Active Healthcare)$ 0.13
    Doxylin 100 mg Tablet (Active Healthcare)$ 0.04
    DOXYLIN 100MG CAPSULE 1 strip / 4 capsules each (Active Healthcare)$ 0.21
    DOXYLIN 100MG TABLET 1 strip / 10 tablets each (Active Healthcare)$ 0.51
    Doxylin 100mg Capsule (Active Healthcare)$ 0.05
    Doxylin 100mg Tablet (Active Healthcare)$ 0.05
    DOXYLIN - DT Dispersible Tablet / 100mg / 10 units (Moraceae Lab)$ 0.57

    References

    1. DailyMed. "DOXYCYCLINE: DailyMed provides trustworthy information about marketed drugs in the United States. DailyMed is the official provider of FDA label information (package inserts).". https://dailymed.nlm.nih.gov/dailyme... (accessed September 17, 2018).
    2. PubChem. "doxycycline". https://pubchem.ncbi.nlm.nih.gov/com... (accessed September 17, 2018).
    3. DrugBank. "doxycycline". http://www.drugbank.ca/drugs/DB00254 (accessed September 17, 2018).

    Reviews

    The results of a survey conducted on ndrugs.com for Doxyhyklan 10% are given in detail below. The results of the survey conducted are based on the impressions and views of the website users and consumers taking Doxyhyklan 10%. We implore you to kindly base your medical condition or therapeutic choices on the result or test conducted by a physician or licensed medical practitioners.

    User reports

    Consumer reported useful

    No survey data has been collected yet


    Consumer reported price estimates

    No survey data has been collected yet


    Consumer reported time for results

    No survey data has been collected yet


    Consumer reported age

    No survey data has been collected yet


    Consumer reviews


    There are no reviews yet. Be the first to write one!


    Your name: 
    Email: 
    Spam protection:  < Type 16 here

    Information checked by Dr. Sachin Kumar, MD Pharmacology

  • | Privacy Policy
    This site does not supply any medicines. It contains prices for information purposes only.
    © 2003 - 2024 ndrugs.com All Rights Reserved